Veterinary Speciality: Oncology
The purpose of this clinical trial is to evaluate a new drug called TAK-981 in dogs with solid tumors (carcinomas/sarcomas). TAK-981 works by both directly killing cancer cells and also by stimulating the immune system to kill cancer cells. Although TAK-981 has been tested extensively in mouse models of cancer and has been well tolerated in healthy dogs, it is not clear whether TAK-981 will be active in dogs (or people) with spontaneous cancers. Therefore, this trial will evaluate TAK-981 in dogs with solid tumors with the goal of identifying the best dose to give, any side effects that may occur, and whether or not the drug can induce shrinkage of tumors.
The ultimate goal of this clinical trial is to shrink your dog’s tumor by direct killing of the tumor cells and by stimulating the immune system to kill the cancer cells. However, given that this is a very early study associated with TAK-981 and we are just beginning to figure out the best dose of drug, it is possible that the TAK-981 will not affect your dog’s tumor at all.
The study will cover all diagnostics (bloodwork, imaging, biopsies, etc) and treatments (TAK-981 administration, supportive medications) associated with the tumor while your dog is enrolled in this study as well as the management of any study related side effects. Following completion of the study, you will receive a $2000 credit at the Foster Hospital for Small Animals for any additional therapy to treat your dog (i.e., surgery, chemotherapy, radiation therapy). Except for the specific financial support described here, any tests or procedures unrelated to this study including treatment of conditions unrelated to the carcinoma/sarcoma (i.e., ear infection, etc) are your responsibility.
Prior to enrollment, your dog will be screened for eligibility by performing blood tests and imaging (x-rays, ultrasound) as needed. If eligible and enrolled, we will next obtain a small biopsy of the tumor, blood samples for analysis, and an aspiration of the local lymph node (if possible). These events occur 4-7 days before TAK-981 administration and are part of the entire screening process. The total study duration is only 7 days from this point on. Your dog will return to the hospital on a Monday or Tuesday to start the study. Your dog will undergo several blood tests/diagnostics prior to and during the course of treatment to monitor blood counts, levels of TAK-981 in the blood, and TAK-981 induced changes in the tumor, draining lymph node, and blood cells.
For questions regarding the clinical trial please fill out this survey: Pet Eligibility Questionnaire
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.